Palvella Therapeutics, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Palvella Therapeutics, Inc. (PVLA) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $103.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-03-31
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $103.00K.
- 2023-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.14M.
- 2023-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.62M.
- 2023-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $6.96M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $103.00K 10-K · filed 2026-03-31 |
| 2023-09-30 | $6.14M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $6.62M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $6.96M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $7.18M 10-K · filed 2023-03-31 |
| 2022-09-30 | $6.86M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $7.63M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $8.48M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $9.01M 10-K · filed 2022-03-02 |
| 2021-09-30 | $9.60M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $10.22M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $26.44M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $9.99M 10-K · filed 2021-03-31 |
| 2020-09-30 | $11.25M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $11.17M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $11.33M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $11.98M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |